TY - JOUR
T1 - Dose-dependent association between amiodarone and severe primary graft dysfunction in orthotopic heart transplantation
AU - Wright, Matthew
AU - Takeda, Koji
AU - Mauro, Christine
AU - Jennings, Douglas
AU - Kurlansky, Paul
AU - Han, Jiho
AU - Truby, Lauren
AU - Stein, Samantha
AU - Topkara, Veli
AU - Garan, Arthur R.
AU - Yuzefpolskaya, Melana
AU - Colombo, Paolo
AU - Naka, Yoshifumi
AU - Farr, Maryjane
AU - Takayama, Hiroo
N1 - Publisher Copyright:
© 2017 International Society for the Heart and Lung Transplantation
PY - 2017/11
Y1 - 2017/11
N2 - Background There is growing concern regarding the association between pre-transplant amiodarone exposure and post-transplant adverse outcomes. We hypothesized that amiodarone use would be associated with the development of severe primary graft dysfunction (PGD) in a dose-dependent manner. Methods This was a retrospective review of 269 adult orthotopic heart transplantation (OHT) recipients at our institution between 2010 and 2014. At the time of OHT, 100 were receiving amiodarone therapy (Group 1) and 169 were not (Group 2). Results Pre-OHT creatinine was higher in Group 1 (1.49 ± 0.63 vs 1.27 ± 0.68 mg/dl, p = 0.011). At time of listing, Group 1 had higher frequency of status 2 (42.0% vs 29.0%), and Group 2 had higher frequency of status 1A (20.7% vs 8.0%; p = 0.009). Severe PGD (mechanical circulatory support within 24 hours post-OHT) was significantly higher in Group 1 (20.0% vs 5.3%, p < 0.001). Pre-OHT amiodarone use was an independent risk factor for severe PGD (odds ratio [OR], 6.05; 95% confidence interval [CI], 2.47–14.83; p < 0.001) and in-hospital mortality (OR, 2.88; 95% CI, 1.05–7.88; p = 0.039) in multivariable analysis. Each 100-mg increase in the day-of-OHT amiodarone dose (OR, 1.55; 95% CI, 1.26–1.90) and each 18,300-mg increase in the 6-month cumulative dose (OR, 1.67; 95% CI, 1.31–2.15) was associated with increased odds of developing severe PGD (p < 0.001 for both). Conclusions Amiodarone use pre-OHT is independently associated with increased incidence of severe PGD and in-hospital mortality and linearly associated with increased incidence of severe PGD in a dose-dependent manner.
AB - Background There is growing concern regarding the association between pre-transplant amiodarone exposure and post-transplant adverse outcomes. We hypothesized that amiodarone use would be associated with the development of severe primary graft dysfunction (PGD) in a dose-dependent manner. Methods This was a retrospective review of 269 adult orthotopic heart transplantation (OHT) recipients at our institution between 2010 and 2014. At the time of OHT, 100 were receiving amiodarone therapy (Group 1) and 169 were not (Group 2). Results Pre-OHT creatinine was higher in Group 1 (1.49 ± 0.63 vs 1.27 ± 0.68 mg/dl, p = 0.011). At time of listing, Group 1 had higher frequency of status 2 (42.0% vs 29.0%), and Group 2 had higher frequency of status 1A (20.7% vs 8.0%; p = 0.009). Severe PGD (mechanical circulatory support within 24 hours post-OHT) was significantly higher in Group 1 (20.0% vs 5.3%, p < 0.001). Pre-OHT amiodarone use was an independent risk factor for severe PGD (odds ratio [OR], 6.05; 95% confidence interval [CI], 2.47–14.83; p < 0.001) and in-hospital mortality (OR, 2.88; 95% CI, 1.05–7.88; p = 0.039) in multivariable analysis. Each 100-mg increase in the day-of-OHT amiodarone dose (OR, 1.55; 95% CI, 1.26–1.90) and each 18,300-mg increase in the 6-month cumulative dose (OR, 1.67; 95% CI, 1.31–2.15) was associated with increased odds of developing severe PGD (p < 0.001 for both). Conclusions Amiodarone use pre-OHT is independently associated with increased incidence of severe PGD and in-hospital mortality and linearly associated with increased incidence of severe PGD in a dose-dependent manner.
KW - amiodarone
KW - extracorporeal membrane oxygenation
KW - heart failure
KW - orthotopic heart transplantation
KW - primary graft dysfunction
UR - http://www.scopus.com/inward/record.url?scp=85020103660&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85020103660&partnerID=8YFLogxK
U2 - 10.1016/j.healun.2017.05.025
DO - 10.1016/j.healun.2017.05.025
M3 - Article
C2 - 28583372
AN - SCOPUS:85020103660
SN - 1053-2498
VL - 36
SP - 1226
EP - 1233
JO - Journal of Heart and Lung Transplantation
JF - Journal of Heart and Lung Transplantation
IS - 11
ER -